Journal ArticleDOI
Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)
S. Tejpar,Marc Peeters,Yves Humblet,Jan B. Vermorken,G. De Hertogh,W. De Roock,Johannes Nippgen,A. von Heydebreck,C. Stroh,E. Van Cutsem +9 more
Reads0
Chats0
TLDR
This work has shown that in pts with mCRC after failure of irinotecan-based therapy, the efficacy could be improved by escalating the dose of cetuximab, and this work aims to demonstrate this in patients with a prior history of central giant cell granuloma.Abstract:
4001 Background: We previously demonstrated in the EVEREST trial that, in pts with mCRC after failure of irinotecan-based therapy, the efficacy could be improved by escalating the dose of cetuximab...read more
Citations
More filters
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht,Edith P. Mitchell,Tarek Chidiac,Carroll Scroggin,Christopher Hagenstad,David R. Spigel,John Marshall,Allen Lee Cohn,David McCollum,Philip J. Stella,Robert Deeter,Seta Shahin,Rafael G. Amado +12 more
TL;DR: The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS, and these combinations are not recommended for the treatment of mCRC in clinical practice.
Journal ArticleDOI
Genetic prognostic and predictive markers in colorectal cancer.
Axel Walther,Elaine C. Johnstone,Charles Swanton,Charles Swanton,Rachel Midgley,Ian Tomlinson,David J. Kerr,David J. Kerr +7 more
TL;DR: There has been an explosive increase in the number of markers thought to be associated with prognosis and treatment outcome in this disease, and this Review attempts to summarize the sometimes confusing findings, and critically assess those markers already in the public domain.
Journal ArticleDOI
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
Salvatore Siena,Andrea Sartore-Bianchi,Federica Di Nicolantonio,Julia Balfour,Alberto Bardelli +4 more
TL;DR: The use of KRAS mutations as a selection biomarker for anti-EGFR monoclonal antibody (eg, panitumumab or cetuximab) treatment is the first major step toward individualized treatment for patients with metastatic colorectal cancer.
Journal ArticleDOI
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab
Bart Jacobs,Wendy De Roock,Hubert Piessevaux,Robin Van Oirbeek,Bart Biesmans,Jef De Schutter,Steffen Fieuws,Jo Vandesompele,Marc Peeters,Jean-Luc Van Laethem,Yves Humblet,Frédérique Penault-Llorca,Gert De Hertogh,Pierre Laurent-Puig,Eric Van Cutsem,Sabine Tejpar +15 more
TL;DR: In this paper, the power of the epidermal growth factor receptor (EGFR) epiregulin (EREG) and amphiregulus (AREG) ligands' expression in primary tumors to predict the outcome in patients with chemorefractory metastatic colorectal cancer (cmCRC) treated with the combination of cetuximab and irinotecan.
Related Papers (5)
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Astrid Lièvre,Jean-Baptiste Bachet,Valérie Boige,Anne Cayre,Delphine Le Corre,Emmanuel Buc,Marc Ychou,Olivier Bouché,Bruno Landi,Christophe Louvet,Thierry André,Frédéric Bibeau,Marie-Danièle Diebold,Philippe Rougier,Michel Ducreux,Gorana Tomasic,Jean-François Emile,Frédérique Penault-Llorca,Pierre Laurent-Puig +18 more